Not yet recruiting
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
NCT07789483· Phase 3· Alexion Pharmaceuticals, Inc.· Source
Contact: Alexion Pharmaceuticals, Inc., Sponsor
Recruiting
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
NCT07816666· Phase 3· AstraZeneca· Source
Recruiting
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
NCT07784725· Phase 3· AstraZeneca· Source
Recruiting
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.
NCT07619131· Phase 3· AstraZeneca· Source
Recruiting
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
NCT07444567· Phase 3· AstraZeneca· Source
Recruiting
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
NCT07662213· Phase 3· AstraZeneca· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM
NCT07608354· Phase 2· AstraZeneca· Source
Recruiting
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
NCT07391657· Phase 3· AstraZeneca· Source
Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719· Phase 3· Arcus Biosciences, Inc.· Source
Contact: Medical Director
Recruiting
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
NCT06549595· Phase 3· AstraZeneca· Source
Active, not recruiting
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873· Phase 3· AstraZeneca· Source
Recruiting
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
NCT05835310· Phase 3· AstraZeneca· Source
Active, not recruiting
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931· Phase 3· Alexion Pharmaceuticals, Inc.· Source
Recruiting
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864· Phase 3· AstraZeneca· Source
Active, not recruiting
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491· Phase 3· AstraZeneca· Source
Recruiting
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
NCT05850234· Phase 1/2· AstraZeneca· Source
Active, not recruiting
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
NCT05583227· Phase 3· AstraZeneca· Source
Active, not recruiting
A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05057494· Phase 3· AstraZeneca· Source
Active, not recruiting
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
NCT04862663· Phase 3· AstraZeneca· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
NCT04512235· Phase 3· Alexion Pharmaceuticals, Inc.· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
NCT04504825· Phase 3· Alexion Pharmaceuticals, Inc.· Source
Active, not recruiting
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
NCT03737643· Phase 3· AstraZeneca· Source
Active, not recruiting
Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.
NCT03616587· Phase 1· AstraZeneca· Source
Active, not recruiting
A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)
NCT03521154· Phase 3· AstraZeneca· Source
Active, not recruiting
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
NCT02671435· Phase 1/2· MedImmune LLC· Source
Active, not recruiting
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
NCT02475681· Phase 3· Acerta Pharma BV· Source
Active, not recruiting
Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
NCT02180711· Phase 1/2· Acerta Pharma BV· Source
Active, not recruiting
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
NCT02029443· Phase 1/2· Acerta Pharma BV· Source